Description: 2021 Life Meeting - Session 8E: Insurance M&A Valuation Methodologies and Considerations 9.1.21 Recording

Description: 2021 Life Meeting - Session 1C: Earnings Pressure Impact on Annuity Product Development and the Insurance-Linked Securities Market

Description: This session series is sponsored by Hannover Re Session 2 - COVID-19: Financial Impacts and Re-shaping Risk and Capital Management Practices COVID-19 has posed significant challenges to health insurers and providers to meet profit targets and maintain strong balance sheets and capitalization levels. As a result, companies are facing an ever-increasing need to better integrate their risk and capital management practices across the enterprise and evaluate a broader set of tools to manage and optimize their capital and liquidity needs. This second session of the COVID-19 series will help you examine the financial impact that COVID-19 has had on the health industry and review how companies are evolving their financial and capital management practices to achieve their strategic goals. It will also outline how structured reinsurance has emerged as an increasingly utilized form of managing capital. By attending this session, you will be able to explain how COVID-19 has impacted the financial performance and capitalization of the health insurance industry, and will gain a basic understanding of alternative ways of managing and optimizing capital, including the use of structired reinsurance.

Description: 2021 Life Meeting - Session 7F: A New Frontier for Reinsurance Accounting - LDTI vs. IFRS 17 9.1.21 Recording

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: Reinsurance has become more frequently used in the annuity market along with large M&A transactions over the past few years. Discuss the market forces and the impact to the product development and pricing. By attending the session, you will: Understand the benefits of reinsuring annuities and the types of reinsurance used for annuities.

Description: IFRS 17 will be effective as of 1 Jan 2023 and provide opportunities as well as challenges to both Direct Writers and Reinsurers across the insurance industry. If the new framework is not fully understood, an implementation can elevate the risk of problems in financial reporting, product development, investment management and more. The transition to IFRS provides an opportunity for companies to optimize the financial position of the enterprise by implementing mitigating strategies to reduce the risks and challenges that IFRS brings to the table.

Description: Join a discussion on the tax implications for direct writers ceding annuity blocks for both onshore and offshore reinsurance arrangements. Get an introduction to the tax consequences of the risk transfer of annuity features and guarantees to reinsurers to reinsurers that are U.S.-based and not U.S. domiciled.

Description: As the size of the life reinsurance market in Bermuda has grown to over half a trillion dollars at the end of 2021, more and more actuaries are getting involved with this 21 square mile North Atlantic island in one way or the other. Come explore a fundamental understanding of the Bermuda solvency framework and an overview of its upcoming changes.

Description: Session 9A: Variable Annuity Inforce Transactions: Trend and Considerations The VA M&A market has been very active in recent years with multiple transactions announced last year alone. Explore the driving forces behind this trend and discuss key considerations for VA inforce transactions.Take a deep dive into key areas of transaction due diligence process. By attending the session, you will: Be able to learn the key drivers of recent VA inforce transactions and the key considerations in the transaction due diligence.